At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 106 enrolled
Drug / intervention
Engerix-Bbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated 20 to 30 Years Ago With Engerix-B
In Brief
A Phase 4 clinical trial evaluating Engerix-B for Hepatitis B Vaccine. Completed, enrolled 106 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the long-term protection against HBV infection in adult subjects, aged 18-40 years vaccinated with three or four doses of Engerix-B 20 to 30 years ago
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B Vaccine
CountriesBelgium, Canada
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionMay 2017
TodayJul 2026
First PostedSep 15, 2016
Enrollment StartOct 11, 2016
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.8 years ago
Interventions
Engerix-Bbiological
Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.